Movement Alert｜Boston Scientific Pre-Market Rise 3.85%, Earnings Beat and Restructuring Plan Continue to Drive Recovery

Market Focus08-14 16:01

On August 14, Boston Scientific rose 3.85% in pre-market trading, trading at $53.68/share, with turnover of $158,000, extending its post-earnings recovery trajectory.

The move continues to be driven by the company's Q2 earnings beat and global restructuring plan disclosed in late July. Boston Scientific reported Q2 adjusted EPS of $0.86, exceeding the consensus estimate of $0.83 by 3.6%, while net sales of $5.44 billion topped the $5.36 billion expectation. The company simultaneously announced a global restructuring program with estimated pre-tax charges of $700 million to $800 million, targeting annualized pre-tax cost savings of $500 million through supply chain optimization and headcount reduction, expected to be substantially complete by end of 2029.

Despite the company lowering full-year adjusted EPS guidance to $3.28-$3.32 versus the $3.36 Street estimate due to Watchman device slowdown and electrophysiology competitive pressures, multiple institutions including UBS and Deutsche Bank maintained Buy ratings with adjusted price targets, supporting the ongoing recovery from post-guidance-cut lows.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1125780977?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-14 16:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125780977","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Boston Scientific Pre-Market Rise 3.85%, Earnings Beat and Restructuring Plan Continue to Drive Recovery","media":"Market Focus","content":"<p><p>On August 14, Boston Scientific rose 3.85% in pre-market trading, trading at $53.68/share, with turnover of $158,000, extending its post-earnings recovery trajectory.</p><p>The move continues to be driven by the company's Q2 earnings beat and global restructuring plan disclosed in late July. Boston Scientific reported Q2 adjusted EPS of $0.86, exceeding the consensus estimate of $0.83 by 3.6%, while net sales of $5.44 billion topped the $5.36 billion expectation. The company simultaneously announced a global restructuring program with estimated pre-tax charges of $700 million to $800 million, targeting annualized pre-tax cost savings of $500 million through supply chain optimization and headcount reduction, expected to be substantially complete by end of 2029.</p><p>Despite the company lowering full-year adjusted EPS guidance to $3.28-$3.32 versus the $3.36 Street estimate due to Watchman device slowdown and electrophysiology competitive pressures, multiple institutions including UBS and Deutsche Bank maintained Buy ratings with adjusted price targets, supporting the ongoing recovery from post-guidance-cut lows.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Boston Scientific Pre-Market Rise 3.85%, Earnings Beat and Restructuring Plan Continue to Drive Recovery</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Boston Scientific Pre-Market Rise 3.85%, Earnings Beat and Restructuring Plan Continue to Drive Recovery\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-14 16:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 14, Boston Scientific rose 3.85% in pre-market trading, trading at $53.68/share, with turnover of $158,000, extending its post-earnings recovery trajectory.</p><p>The move continues to be driven by the company's Q2 earnings beat and global restructuring plan disclosed in late July. Boston Scientific reported Q2 adjusted EPS of $0.86, exceeding the consensus estimate of $0.83 by 3.6%, while net sales of $5.44 billion topped the $5.36 billion expectation. The company simultaneously announced a global restructuring program with estimated pre-tax charges of $700 million to $800 million, targeting annualized pre-tax cost savings of $500 million through supply chain optimization and headcount reduction, expected to be substantially complete by end of 2029.</p><p>Despite the company lowering full-year adjusted EPS guidance to $3.28-$3.32 versus the $3.36 Street estimate due to Watchman device slowdown and electrophysiology competitive pressures, multiple institutions including UBS and Deutsche Bank maintained Buy ratings with adjusted price targets, supporting the ongoing recovery from post-guidance-cut lows.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BSX","symbol_name":"波士顿科学","start_time":0,"source_url":"","article_id":"1125780977","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125780977","pubTimestamp":1786694465,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 14, Boston Scientific rose 3.85% in pre-market trading, trading at $53.68/share, with turnover of $158,000, extending its post-earnings recovery trajectory.The move continues to be driven...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BSX":"波士顿科学"},"translate_title":"走势警报|波士顿科学盘前上涨3.85%，盈利超出预期和重组计划继续推动复苏","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BSX":1},"content_text":"On August 14, Boston Scientific rose 3.85% in pre-market trading, trading at $53.68/share, with turnover of $158,000, extending its post-earnings recovery trajectory.The move continues to be driven by the company's Q2 earnings beat and global restructuring plan disclosed in late July. Boston Scientific reported Q2 adjusted EPS of $0.86, exceeding the consensus estimate of $0.83 by 3.6%, while net sales of $5.44 billion topped the $5.36 billion expectation. The company simultaneously announced a global restructuring program with estimated pre-tax charges of $700 million to $800 million, targeting annualized pre-tax cost savings of $500 million through supply chain optimization and headcount reduction, expected to be substantially complete by end of 2029.Despite the company lowering full-year adjusted EPS guidance to $3.28-$3.32 versus the $3.36 Street estimate due to Watchman device slowdown and electrophysiology competitive pressures, multiple institutions including UBS and Deutsche Bank maintained Buy ratings with adjusted price targets, supporting the ongoing recovery from post-guidance-cut lows.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1125780977","isCrawlerRequest":true}